Douglas Miehm
Stock Analyst at RBC Capital
(2.22)
# 2,636
Out of 4,711 analysts
42
Total ratings
48.28%
Success rate
-4.06%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $141 → $143 | $114.64 | +24.74% | 5 | Dec 11, 2024 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $10 → $11 | $7.47 | +47.26% | 18 | Nov 1, 2024 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $20 → $23 | $18.00 | +27.78% | 10 | Oct 22, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $9.03 | -11.41% | 9 | Feb 16, 2024 |
Ligand Pharmaceuticals
Dec 11, 2024
Maintains: Outperform
Price Target: $141 → $143
Current: $114.64
Upside: +24.74%
Bausch Health Companies
Nov 1, 2024
Maintains: Sector Perform
Price Target: $10 → $11
Current: $7.47
Upside: +47.26%
Bausch + Lomb
Oct 22, 2024
Maintains: Outperform
Price Target: $20 → $23
Current: $18.00
Upside: +27.78%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $9.03
Upside: -11.41%